Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ford Motor Company (F) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ford Motor Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Ford Motor Company trades at $13.83 (market cap $55.75B). The key difference: Ford Motor Company is the larger of the two by market cap, and Ford Motor Company pays a 4.29% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | F | |
|---|---|---|
Market Cap | $29.60B | $55.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $17.44 |
52-Week Low | $205.48 | $11.21 |
Enterprise Value | $27.56B | $187.71B |
Dividend Yield | — | 4.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Ford Motor Company (F) trades at $13.865, down 1.07% on the day, with a bearish technical signal. Recent earnings show volatility, with Q2 2026 beating expectations but Q4 2025 missing. The company reported a net loss of $8.18B in 2025 despite $187.27B revenue, though operating cash flow remains strong at $21.28B. News highlights the upcoming Fathom EV truck priced at $28,350, targeting affordability in 2027.
The outlook is mixed; low P/E of 11.84 and analyst consensus price target of $16.18 suggest potential upside, but negative net income margin and high debt pose risks. Investor sentiment is cautious amid EV transition costs and competitive pressures, with 38.3% of analysts rating Buy. Key opportunities include new affordable models and strong cash flow, while execution on profitability remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
